A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Rheumatoid Arthritis

Interventions

DRUG

namilumab (MT203)

administered three times, subcutaneous in the abdomen

DRUG

Placebo

administered three times, subcutaneous in the abdomen

Trial Locations (2)

Nycomed Investigational Site, Sofia

Nycomed Investigational Site, Leids